(E)-2,4-dimethylpent-2-en-1-ol | 3876-56-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-2,4-dimethylpent-2-en-1-ol
• CAS: 3876-56-0
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: FRNHNENZDWMNBU-QPJJXVBHSA-N

物化性质

• 沸点：
  79-80 °C(Press: 22 Torr)
• 密度：
  0.843±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-2,4-dimethylpent-2-en-1-ol 在 manganese(IV) oxide 作用下， 以 乙醚 为溶剂， 生成 (2E,4E)-ethyl 4,6-dimethylhepta-2,4-dienoate
  参考文献：
  名称：

  Acyl tetramic acids. 6. Synthesis of 3-dienoyl tetramic acids related to streptolydigin and tirandamycin

  摘要：

  DOI：

  10.1021/ja00481a036
• 作为产物：
  描述：

  (E)-2,4-dimethylpent-2-enoic acid 在 lithium aluminium tetrahydride 作用下， 生成 (E)-2,4-dimethylpent-2-en-1-ol
  参考文献：
  名称：

  Unsaturated acids and macrocyclic lactones Communication 14. Configuration of meso-2,4-dimethyl-1,3,5-pentanetriol and ot the asymmetric center at C3 in erythromycin and oleandomycin

  摘要：

  DOI：

  10.1007/bf00846289

文献信息

• DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20160194290A1

  公开（公告）日：2016-07-07

  A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.

  化合物的结构式[I]或其药用盐：其中每个符号的定义如规范中所述。
• AMINOTHIAZOLE DERIVATIVE
  申请人：Yabuuchi Tetsuya

  公开号：US20120220767A1

  公开（公告）日：2012-08-30

  A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase γ inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

  由式（1）表示的化合物或其药学上可接受的盐，具有PI3激酶γ抑制作用，可用作关节风湿、克罗恩病、肠易激综合征、干燥综合征、多发性硬化、系统性红斑狼疮、哮喘、特应性皮炎、动脉硬化、器官移植排斥、癌症、视网膜病变、牛皮癣、关节病变、年龄相关性黄斑变性、2型糖尿病、胰岛素抵抗、肥胖、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）、高脂血症等疾病的预防或治疗剂。
• Thiazole, Imidazole and Oxazoline Based N,P-Ligands for Palladium-Catalyzed Cycloisomerization of 1,6-Enynes
  作者：Xu Quan、Jianguo Liu、Wangchuk Rabten、Simone Diomedi、Thishana Singh、Pher G. Andersson

  DOI：10.1002/ejoc.201600468

  日期：2016.7

  A series of N,P-ligands were prepared and evaluated in the asymmetric palladium-catalyzed cycloisomerization of allyl propargyl ether substrates. The reactivity and enantioselectivity of the reaction was shown to be highly dependent on the chiral skeleton of the ligand structures with ee's ranging from 22–99 %. The proton source had a significant impact on the enantioselectivity. The generation of

  在烯丙基炔丙基醚底物的不对称钯催化环异构化中制备并评估了一系列 N,P-配体。该反应的反应性和对映选择性高度依赖于配体结构的手性骨架，ee 的范围为 22-99%。质子源对对映选择性有显着影响。从甲酸生成氢化钯导致最高的ee。基于提议的过渡态的选择性模型用于预测和解释反应的对映体结果。
• [EN] HYDROGENATION OF CARBONYLS WITH TETRADENTATE PNNP LIGAND RUTHENIUM COMPLEXES<br/>[FR] HYDROGÉNATION DE CARBONYLES AVEC DES COMPLEXES DE RUTHÉNIUM - LIGAND TÉTRADENTATE PNNP
  申请人：FIRMENICH & CIE

  公开号：WO2019175158A1

  公开（公告）日：2019-09-19

  The present invention relates to catalytic hydrogenation processes, using Ru complexes with tetradentate ligands of formula L in hydrogenation processes for the reduction of ketone, aldehyde, ester or lactone into the corresponding alcohol or diol respectively. The described processes use a ruthenium complex of the formula (1) as defined below, and where the ligand (L) is defined by the Markush formula shown above.

  本发明涉及催化加氢过程，使用具有四齿配体L的Ru配合物在加氢过程中将酮、醛、酯或内酯还原为相应的醇或二醇。所述过程使用下文所定义的化学式（1）的钌配合物，并且配体（L）由上述Markush式定义。
• Divergent Regioselectivity in the Synthesis of Trisubstituted Allylic Alcohols by Nickel- and Ruthenium-Catalyzed Alkyne Hydrohydroxymethylation with Formaldehyde
  作者：Cory C. Bausch、Ryan L. Patman、Bernhard Breit、Michael J. Krische

  DOI：10.1002/anie.201101496

  日期：2011.6.14

  Stoichiometric metals banned: Nonsymmetrically disubstituted alkynes were converted into primary trisubstituted allylic alcohols upon exposure to paraformaldehyde in the presence of nickel or ruthenium catalysts, which exhibit complementary regioselectivity and complete stereoselectivity in the absence of exogenous reducing agents (see scheme).

  禁止化学计量的金属：在镍或钌催化剂的存在下，低对称的二取代炔烃在暴露于低聚甲醛中时会转化为伯三取代的烯丙基醇，在没有外源还原剂的情况下，它们具有互补的区域选择性和完全的立体选择性（参见方案）。